Forma Therapeutics Holdings (FMTX) Reports In-Line Q1 EPS

Forma Therapeutics Holdings (NASDAQ: FMTX) reported Q1 EPS of ($0.76), in-line with the analyst estimate of ($0.76).

“During the first quarter, we successfully completed the multiple ascending dose portion of our Phase 1 trial in sickle cell disease, and despite challenges from the COVID-19 pandemic also began enrolling patients in the Phase 2/3 trial of FT-4202, called The Hibiscus Study, as well as in the Phase 1 trial of FT-7051 for metastatic castration resistant prostate cancer,” said Frank Lee, President and Chief Executive Officer of Forma. “We look forward to sharing additional pipeline results over the course of 2021 in our mission to transform the lives of people living with rare hematologic diseases and cancers.“

For earnings history and earnings-related data on Forma Therapeutics Holdings (FMTX) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• BWS Financial Downgrades Inter Parfums (IPAR) to Sell
• Motorsport Games Inc. (MSGM) Tops Q2 EPS by 33c